MAR 20, 2019 11:39 AM PDT

First Drug for Postpartum Depression

WRITTEN BY: Nouran Amin

The U.S. Food and Drug Administration recently approved the first ever drug specifically for the treatment of postpartum depression--a common and often devastating condition for new mothers which interferes with the maternal-infant bond. The approval of the drug came after the success of two clinical trials."Postpartum depression is a serious condition that, when severe, can be life-threatening," noted the FDA's Dr. Tiffany Farchione, who is acting director of the Division of Psychiatry Products in the agency's Center for Drug Evaluation and Research. "Women may experience thoughts about harming themselves or harming their child."

The drug is called Zulesso (brexanolone) and would be delivered intravenously.

"There is tremendous stigma around postpartum depression for women. Many women experience great shame and feel inadequate as mothers if they struggle with depression at a time that is supposed to be joyous ," says Dr. Martha Wald, a psychiatrist and psychoanalyst at Duke University, in Winston-Salem, N.C. "Because of this stigma, many women choose to not seek help and endure great suffering in silence," she said. "Postpartum depression affects 15 to 20 percent of the general population, and at least half of this group goes untreated. As more targeted treatments like this become available, more mothers are likely to seek and benefit from treatment."

Zulesso is different than any other antidepressant as it specifically acts on the main inhibitory neurotransmitter system of the brain, the GABA system. The drug also cocnatins an aturally occurring steroid in the body—allopregnanolone. "Allopregnanolone is known to modulate the stress response system in humans, which has been shown to be abnormally functioning in women with postpartum depression," explained Dr. Kristina Deligiannidis, the lead investigator on the clinical trials that led to Zulesso's approval.

Source: MedicalXpress.com

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
SEP 15, 2020
Drug Discovery & Development
Turmeric Better than Placebo for Osteoarthritis Pain
SEP 15, 2020
Turmeric Better than Placebo for Osteoarthritis Pain
Researchers from the University of Tasmania in Australia have found that an extract from turmeric is more effective than ...
NOV 03, 2020
Cardiology
A New Peptide Could Help Repair and Protect the Heart During Ischemia Reperfusion Injury
NOV 03, 2020
A New Peptide Could Help Repair and Protect the Heart During Ischemia Reperfusion Injury
Cardiovascular disease is one of the most common causes of death in the world. Although we have many treatments against ...
NOV 06, 2020
Drug Discovery & Development
Anti-depressant Shows Promise in Treating Childhood Cancer
NOV 06, 2020
Anti-depressant Shows Promise in Treating Childhood Cancer
Researchers from Sweden and the US have found that a commonly prescribed antidepressant may help stop the growth of a ca ...
NOV 11, 2020
Cancer
A New CDK Inhibitor Could Help with Unresponsive Liver Cancer
NOV 11, 2020
A New CDK Inhibitor Could Help with Unresponsive Liver Cancer
Amongst the most common targets of anti-cancer drugs are small regulatory molecules called cyclin-dependent kinases (CDK ...
NOV 12, 2020
Immunology
The Enzyme That Keeps Viruses In Stealth Mode
NOV 12, 2020
The Enzyme That Keeps Viruses In Stealth Mode
Some viral infections just don’t go away. The hepatitis C virus, for instance, can result in life-long chronic inf ...
NOV 22, 2020
Cannabis Sciences
Public Believes CBD is Cure-All Despite Lack of Evidence
NOV 22, 2020
Public Believes CBD is Cure-All Despite Lack of Evidence
Many people think that cannabidiol (CBD), a non-psychoactive compound in cannabis, can reduce symptoms from various cond ...
Loading Comments...